Phibro Animal Health CEO Sells Over 110,000 Shares Amid Market Activity

On February 5, 2024, Jack Bendheim, the CEO of Phibro Animal Health Corporation (NASDAQ: PAHC), sold 110,842 shares of the company’s stock. This transaction was valued at approximately $5,362,535.96, with the shares sold at an average price of $48.38. Following this sale, Bendheim’s direct ownership in Phibro decreased significantly, bringing his total shares down to 122,958, valued at around $5,948,708.04, which represents a 47.41% reduction in his stake.

This transaction was documented in a filing with the U.S. Securities and Exchange Commission (SEC). Further context on the company’s stock performance reveals a recent decline; during midday trading on a Monday, shares of NASDAQ: PAHC dropped by 2.3%, reaching $51.85 with a trading volume of 373,486 shares, surpassing the average volume of 256,830.

Financial Performance Overview

Phibro Animal Health holds a market capitalization of approximately $2.10 billion. The company maintains a quick ratio of 1.22, a current ratio of 3.05, and a debt-to-equity ratio of 2.14. Its stock’s 50-day moving average stands at $40.10, while the 200-day moving average is at $38.43. Over the past year, the stock has fluctuated between a low of $16.16 and a high of $56.30.

Recently, the company declared a quarterly dividend of $0.12, set to be paid on March 25, 2024. Shareholders recorded on March 4 will receive this dividend, representing an annualized payout of $0.48 and a yield of 0.9%. The current dividend payout ratio stands at 21.33%.

Analyst Insights and Market Reactions

Market analysts continue to assess Phibro Animal Health’s performance. On February 5, Morgan Stanley set a target price of $49.00 for the stock, while Zacks Research upgraded its recommendation from “hold” to “strong-buy.” Additionally, JPMorgan Chase & Co. raised its price target from $45.00 to $50.00, providing the company with an “overweight” rating.

The consensus among analysts presents a mixed outlook: one equity research analyst has given a “strong buy” rating, two have rated it as “buy,” another two categorized it as “hold,” and two analysts suggested a “sell.” The average rating remains at “hold,” with an average price target of $34.40 according to data from MarketBeat.

Recent institutional activities indicate a shift in investment strategies. 1620 Investment Advisors Inc. increased its stake in Phibro by 77.4% during the last quarter, now holding 676 shares valued at $25,000. Similarly, Farther Finance Advisors LLC raised its holdings by 113.2%, now owning 727 shares worth $27,000. Notably, institutional investors collectively own 99.34% of the stock.

Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey, and specializes in developing, manufacturing, and marketing a diverse range of pharmaceutical products and mineral nutrition solutions aimed at enhancing the health and productivity of livestock, companion animals, and aquaculture species. Its offerings include vaccines, anti-infective therapies, and specialty feed additives, among others.

As market dynamics shift, stakeholders will be watching closely to see how these developments impact the company and its stock performance in the coming months.